Dastgheib v. Genentech, Inc.

457 F. Supp. 2d 536, 2006 U.S. Dist. LEXIS 78891, 2006 WL 3059946
District Court, E.D. Pennsylvania·Decided October 27, 2006·No. Civil Action 04-1283·Published·Cited by 7 cases

Opinion

MEMORANDUM

ROBRENO, District Judge.

Before the Court is Genentech, Inc.’s Motion for Judgment of Dismissal or in the Alternative to Strike Plaintiffs Jury Demand on the Unjust Enrichment Claim 1 (doc. no. 183). Resolution of the motion turns on whether the unjust enrichment claim is legal or equitable. For the reasons that follow, the motion will be denied.

I. BACKGROUND

The relevant facts in this case are as follows. 2 Dr. Kourosh A. Dastgheib (“Dastgheib”), an ophthalmologist, alleges that he provided certain human tissue samples and research materials to Gene-tech, Inc. (“Genetech”), a biotechnology company, after Genentech represented that it would give Dastgheib recognition in the medical and scientific community for his scientific discovery, as well as one percent of gross sales of any drug that Genen-tech developed using Dastgheib’s research. Dastgheib further alleges that he sent Genentech the requested research materi- *538 ais and that Genentech developed a drug using them, but that Genentech does not intend to give him any portion of the gross revenues nor any express recognition for his scientific discoveries.

As part of his action against Genentech, Dastgheib asserts a claim for unjust enrichment, 3 which he described in his complaint as follows:

Genentech stands to gain astronomically from Dr. Dastgheib’s discovery ..., while Dr. Dastgheib, without the protection to which he is entitled by law, will not participate in the fruits of his efforts. Genentech has been unjustly enriched. Dr. Dastgheib is entitled to damages commensurate with the benefit conferred upon Genentech.

Pl.’s Compl. at ¶¶ 48-50 (doc. no. 1) (emphasis added).

Under North Carolina law, which applies to Dastgheib’s claims in this case, “[wjhen one [party] confers a benefit upon another which is not required by a contract ..., the recipient thereof is often unjustly enriched and will be required to make restitution therefor.” Siskron v. Temel-Peck Enterprises, 26 N.C.App. 387, 216 S.E.2d 441, 444 (1975). Moreover, throughout the proceedings in this case, Dastgheib has made clear that he seeks, as a measure of the benefit Dastgheib conferred upon Genentech, the disgorgement of Genentech’s profits derived from its use of Dastgheib’s research materials. Thus, in the Court’s memorandum in support of its denial of Genentech’s motion for summary judgment, the Court stated:

The Court finds that it appears that plaintiffs remedies under the unjust enrichment theory are not necessarily limited to the fair market value of the tissue samples and methodologies and the reasonable value of his time and expenses in procuring them. Rather, under North Carolina, in certain circumstances, defendant’s profits may be available in a claim for unjust enrichment.

Dastgheib v. Genentech, Inc., 2006 WL 120052 at *8-9 (E.D.Pa. Jan.13, 2006).

In discussing Genentech’s subsequent motion to exclude the testimony of Dast-gheib’s expert regarding unjust enrichment damages, the Court further elaborated on the nature of Dastgheib’s unjust enrichment claim, stating that:

[T]he jury will be asked to evaluate the appropriate damages remedy in light of the purposes of unjust enrichment — to disgorge the profits that would be inequitable for defendant to retain — and in making that determination, the jury may consider numerous equitable factors, including but not limited to, the relative extent of plaintiffs contributions.

Dastgheib v. Genentech, Inc. 438 F.Supp.2d 546, 552 (E.D.Pa.2006).

This exposition of Dastgheib’s claim is consistent with North Carolina law. Under North Carolina law, the kind of restitution that Dastheib seeks “is not aimed at compensating the plaintiff, but at forcing the defendant to disgorge benefits that it would be unjust for him to keep.” Booher v. Frue, 86 N.C.App. 390, 358 S.E.2d 127, 129 (1987). “A plaintiff may receive a windfall in some cases, but this is acceptable in order to avoid any unjust enrichment on the defendant’s part.” Id.

Thus, it is conceivable that at trial a jury could find that Dastgheib’s unjust enrichment claim entitles Dastgheib to a sum of damages that are greater than his poten *539 tial damages for fraud and unfair and deceptive practices. Unlike unjust enrichment, the purpose of these latter claims is to place “plaintiff in the same position as if the fraud had not been practiced upon him.” Godfrey v. Res-Care, Inc., 165 N.C.App. 68, 598 S.E.2d 396, 404 (2004).

On the eve of trial, 4 Genentech brought the instant motion to dismiss that claim. Arguing that unjust enrichment is an equitable claim, Genentech contends that Dast-gheib should be barred from maintaining this type of claim because he has an adequate remedy at law, namely, his claims of fraud and violation of North Carolina’s Unfair and Deceptive Trade Practices Act. 5 Genentech also asks, alternatively, to strike plaintiffs jury demand with respect to the unjust enrichment claim because equitable claims are not triable to a jury.

II. DISCUSSION

A. Legal Standards

The premise of both Genentech’s arguments is that Dastgheib’s claim for unjust enrichment seeking disgorgement of profits is an equitable claim. Therefore, first and foremost, the Court will examine whether that claim is legal or equitable.

“In diversity cases, of course, the substantive dimension of the claim asserted finds its source in state law, ... but the characterization of that state-created claim as legal or equitable ... must be made by recourse to federal law.” Simler v. Conner, 372 U.S. 221, 222, 83 S.Ct. 609, 9 L.Ed.2d 691 (1963); Heater v. Kispeace, 2005 WL 2456008 at *5 (E.D.Pa. 0ct.05, 2005). Fortunately, the Supreme Court has visited this issue at some length in the recent past.

In Chauffeurs, Teamsters & Helpers Local No. 391 v. Terry, 494 U.S. 558, 110 S.Ct. 1339, 108 L.Ed.2d 519 (1990), the Supreme Court succinctly reiterated the two-part used to determine if a claim is equitable or legal:

Free access — add to your briefcase to read the full text and ask questions with AI

Dastgheib v. Genentech, Inc., 457 F. Supp. 2d 536, 2006 U.S. Dist. LEXIS 78891, 2006 WL 3059946 (E.D. Pa. 2006).

457 F. Supp. 2d 536 (Dastgheib v. Genentech, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related